Although this endpoint was not met, belimumab reduced memory B cells, which suggests it may have a role in long-term desensitization strategies in patients with pre-existing DSA.[13] B cell maturation antigen (BCMA), which APRIL and BLyS bind to on the surface of memory B and plasma cells, has been targeted in multiple myeloma clinical trials using anti-BCMA antibody with promising results.[14, 15]. Here, TNFRSF17 is linked to AL amyloidosis.